receives - Switzerland

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

2026-07-16

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of…

RRoche

Roche receives CE Mark for blood test to identify tuberculosis infection

2026-07-09

The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health…

NNovartis

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

2026-07-02

First gene replacement therapy in the EU for broad population with SMA, including children two years and older,…

SSwitzerland

Alternative Ballistics Corporation (OTCQB: ALBC) Receives Swiss Academy Award for Global Impact Through its Chairperson Vanessa Luna

2026-06-03

International recognition highlights Alternative Ballistics’ leadership in next-generation less-lethal public safety technologies Supports the Company’s expanding commercial opportunities…

NNovartis

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

2026-04-24

Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment…

RRoche

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

2026-04-13

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple…

RRoche

Nuvau Closes Acquisition of Matagami Property from Glencore

2026-03-18

The Elecsys ApoE4 test is the first CE marked in-vitro diagnostic immunoassay to identify individuals carrying the ApoE4…